UNSPSC 51181918: Clometerone or clometherone

This classification denotes an antiestrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01L3E93T4C. European Medicines Agency schedules Clometerone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06719MIG. Clometerone generally arises in the molecular formula C22H31CLO2. The term CLOMETERONE is an International Non-Proprietary Name or INN. CLOMETERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Clometerone or clometherone bears US NLM identifiers UMLS ID C2347808 and NCI Concept Code C74147. SMILES: CLC1CC2C3C(C(C(C3)C)C(=O)C)(CCC2C2(C1=CC(=O)CC2)C)C.

UNSPSC 51181918 Clometerone or clometherone, a Commodity code, addresses pharmaceutical manufacturing and supply chain participation in state and local cooperative purchasing programs for generic medications and over-the-counter products. State and local governments—primarily state health and human services agencies and departments of administration—buy access to manufacturer pricing and product availability under multi-source pharmaceutical agreements that feed supply chains through authorized wholesalers to government facilities, clinics, and institutions. The work involves manufacturers certifying compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintaining contractual relationships with specified authorized wholesalers, submitting detailed product specifications including National Drug Codes and packaging configurations, and offering pricing flexibility through formats such as flat price, net price structures, or WAC-minus arrangements. Manufacturers must also carry comprehensive insurance including $5 million commercial general liability coverage, maintain minimum shelf life and expiration-date standards, and accept performance penalty assessments for reporting or onboarding failures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. The procurement emphasizes price competitiveness (weighted at 75 percent of evaluation) alongside compliance with administrative data formats, EDI capability, and cGMP and DSCSA certification. Awarded vendors will be provided to authorized wholesalers (AmerisourceBergen Drug Corporation/Cencara, Cardinal Health, and Morris & Dickson Co., LLC) by May 15, 2026, with resulting contracts effective July 1, 2026 through a two-year term with optional extensions. All submissions require detailed product information in designated Excel-to-CSV format and must be made through the ePro procurement system.